Form 4: Compass Therapeutics GC Awarded Significant Equity

Compass Therapeutics General Counsel Jonathan Anderman received 150,000 restricted stock units and 720,000 stock options.

Summary

• Jonathan Anderman, General Counsel of Compass Therapeutics, Inc. (CMPX), was granted 150,000 restricted stock units (RSUs) and 720,000 stock options.
• The transaction date for these awards was January 2, 2026.
• Each RSU represents a contingent right to receive one share of common stock, subject to service-based vesting conditions.
• The RSUs will vest in four equal annual installments, with the first vesting on January 2, 2027.
• The stock options have an exercise price of $5.17 per share and will vest over 48 substantially equal monthly installments, commencing February 2, 2026.
• The stock options have an expiration date of January 2, 2036.
• Following these transactions, Mr. Anderman beneficially owns 171,000 shares of common stock (including 150,000 unvested RSUs) and 720,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it reflects standard executive compensation practices aimed at aligning management interests with shareholders and retaining key talent, without indicating any negative operational or financial news.

Positives

• The equity awards align the General Counsel's interests with those of shareholders, incentivizing long-term company performance.
• The vesting schedules for both RSUs and stock options serve as a retention mechanism for key management personnel.

Negatives

• The issuance of new equity awards, upon vesting and exercise, can lead to a minor dilutive effect on existing shareholders.

Future Outlook

The equity awards, with their multi-year vesting schedules, indicate a long-term commitment from the General Counsel to the company's future performance and growth, aligning his incentives with the company's strategic objectives.

Industry Context

Equity compensation, including restricted stock units and stock options, is a standard practice across the biotechnology and pharmaceutical industries for attracting, retaining, and incentivizing key executives and aligning their interests with long-term shareholder value.

Comparison to Industry Standards

• The grant of restricted stock units and stock options to a General Counsel is a common form of executive compensation in publicly traded companies, particularly within the biotech sector.
• The vesting schedules (four years for RSUs, four years for options) are typical for such awards, designed to promote long-term retention and performance alignment, consistent with industry benchmarks for executive incentive plans.

Stakeholder Impact

• Shareholders: Potential minor dilution upon vesting and exercise of awards, but also increased alignment of management's interests with long-term shareholder value.
• Employees: May signal stability in executive leadership and a commitment to long-term growth, potentially boosting morale.

Next Steps

• The restricted stock units will begin vesting annually on January 2, 2027.
• The stock options will begin vesting monthly on February 2, 2026.

Key Dates

Keywords

Compass Therapeutics, CMPX, Jonathan Anderman, General Counsel, Restricted Stock Units, RSU, Stock Options, Equity Compensation, Insider Transaction, SEC Form 4